Cohrs, Stefan

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Neumann, A. C."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Huther, G."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Cohrs, Stefan"],["dc.date.accessioned","2018-11-07T10:56:36Z"],["dc.date.available","2018-11-07T10:56:36Z"],["dc.date.issued","2005"],["dc.format.extent","263"],["dc.identifier.isi","000232591900169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50052"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Reduced cortisol excretion in healthy subjects under treatment with ziprasidone"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","414"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","420"],["dc.bibliographiccitation.volume","174"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Guan, Zhenghua"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:47:56Z"],["dc.date.available","2018-11-07T10:47:56Z"],["dc.date.issued","2004"],["dc.description.abstract","Rationale. Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is a frequent finding in psychiatric disorders, including psychotic depression and schizophrenia. Conflicting results exist concerning the influence of antipsychotics on the HPA-axis. Objective. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the effect of quetiapine on nocturnal urinary cortisol and melatonin excretion in 13 healthy male subjects under conditions of undisturbed and experimentally disturbed sleep. Methods. Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Placebo, quetiapine 25 mg or quetiapine 100 mg was administered orally 1 h before bedtime on nights 1 and 2. Urine produced during the 8-h bedtime period was collected for later determination of cortisol and melatonin concentrations by standard radioimmunoassays. Results. MANOVA showed a significant effect for N1 vs. N2 with elevated total amount of cortisol (p<0.005) and melatonin (p<0.05) excretion after acoustic stress. Both quetiapine 25 mg and 100 mg significantly (p<0.0005) reduced the total amount of cortisol excretion in comparison to placebo. No interaction effect of stress condition was observed. There was no effect of quetiapine on melatonin levels. Conclusion. The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects. This finding may be an important aspect in quetiapine's mode of action in different patient populations."],["dc.identifier.doi","10.1007/s00213-003-1766-6"],["dc.identifier.isi","000222646700013"],["dc.identifier.pmid","14735295"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48081"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0033-3158"],["dc.title","Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","87"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Sleep Research"],["dc.bibliographiccitation.lastpage","93"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Kirov, Roumen"],["dc.contributor.author","Kinkelbur, J."],["dc.contributor.author","Heipke, S."],["dc.contributor.author","Kostanecka-Endress, T."],["dc.contributor.author","Westhoff, M."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Banaschewski, Tobias"],["dc.contributor.author","Rothenberger, A."],["dc.date.accessioned","2018-11-07T10:50:47Z"],["dc.date.available","2018-11-07T10:50:47Z"],["dc.date.issued","2004"],["dc.description.abstract","The aim of the study was to characterize the sleep pattern in children with attention deficit/hyperactivity disorder (ADHD). By means of polysomnography (PSG), sleep patterns were studied in 17 unmedicated preadolescent boys rigorously diagnosed with ADHD and 17 control boys precisely matched for age and intelligence. Although ADHD children did not display a general sleep alteration, major PSG data showed a significant increase in the duration of the absolute rapid eye movement (REM) sleep and the number of sleep cycles in ADHD group when compared with controls. In addition, REM sleep latency tended to be shorter in ADHD children. These results suggest that in ADHD children, a forced REM sleep initiation may produce a higher incidence of sleep cycles and may also contribute to an increased duration of the absolute REM sleep. The overall pattern of the findings implies that a forced ultradian cycling appears characteristic for the sleep in ADHD children, which may be related to alterations of brain monoamines and cortical inhibitory control accompanying the ADHD psychopathology."],["dc.identifier.doi","10.1111/j.1365-2869.2004.00387.x"],["dc.identifier.isi","000189141800011"],["dc.identifier.pmid","14996040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48733"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0962-1105"],["dc.title","Is there a specific polysomnographic sleep pattern in children with attention deficit/hyperactivity disorder?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","867"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.lastpage","874"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Eggert, S."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Brunner, E."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Hajak, Goran"],["dc.date.accessioned","2018-11-07T10:47:06Z"],["dc.date.available","2018-11-07T10:47:06Z"],["dc.date.issued","2004"],["dc.description.abstract","Study Objectives: The prostaglandin D system plays an important role in animal sleep. In humans, alterations in the prostaglandin D system have been found in diseases exhibiting sleep disturbances as a prominent symptom, such as trypanosoma infection, systemic mastocytosis, bacterial meningitis, major depression, or obstructive sleep apnea. Assessment of this system's activity in relation to human physiologic sleep was the target of the present study. Design: Serum concentrations of lipocalin-type prostaglandin D synthase (L-PGDS, former P-trace), and plasma levels of the pineal hormone melatonin were measured in 20 healthy humans (10 women, 10 men; aged: 23.3 +/- 2.39 years) at 4-hour intervals over a period of 5 days and nights, which included physiologic sleep, rapid eye movement sleep deprivation, and total sleep deprivation. In addition, the serum L-PGDS and plasma melatonin levels of 6 subjects were determined under conditions of bright white (10,000 lux) or dark red light (< 50 lux) in a crossover design during total sleep deprivation. Nocturnal blood sampling was performed by a through-the-wall tube system. L-PGDS was measured by an automated immunonephelometric assay, and melatonin was analyzed by direct radioimmunoassay. Results: Serum L-PGDS concentrations showed marked time-dependent changes with evening increases and the highest values at night (P < .0005). This nocturnal increase was suppressed during total sleep deprivation (P < .05), independent of external light conditions and melatonin secretion. Rapid eye movement sleep deprivation had no impact on circulating L-PGDS levels. Conclusions: The circadian L-PGDS pattern and its suppression by total sleep deprivation indicate an interaction of the prostaglandin D system and human sleep regulation. L-PGDS measurements may well provide new insights into physiologic and pathologic sleep regulation in humans."],["dc.identifier.isi","000223451400008"],["dc.identifier.pmid","15453544"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47897"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.relation.issn","0161-8105"],["dc.title","Prostaglandin D synthase (beta-trace) in healthy human sleep"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","23"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Psychosomatic Research"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Kostanecka-Endress, T."],["dc.contributor.author","Banaschewski, Tobias"],["dc.contributor.author","Kinkelbur, J."],["dc.contributor.author","Wullner, I."],["dc.contributor.author","Lichtblau, S."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Woerner, W."],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Rothenberger, A."],["dc.date.accessioned","2018-11-07T10:38:02Z"],["dc.date.available","2018-11-07T10:38:02Z"],["dc.date.issued","2003"],["dc.description.abstract","Objective: To evaluate objective data on sleep quantity/quality and motor activity during night sleep in children with Tourette syndrome (TS). Method: Polysomnography of 17 unmedicated TS children (ages: 7;11-15;5, mean: 11;10 years) without comorbid attention-deficit hyperactivity disorder (ADHD) was compared with 16 age-, sex- and IQ-matched healthy controls. Sleep analyses according to the procedure of Rechtschaffen and Kales were supplemented by counting epochs with short arousal-related movements (less than or equal to15 s), thus allowing to calculate correlations between motor activity and sleep parameters. Results: Children with TS demonstrated changes in sleep parameters, including longer sleep period time, longer sleep latency, reduced sleep efficiency, and prolonged wakefulness after sleep onset. Their sleep profiles showed significantly more time awake and less sleep stage II. However, REM sleep variables, slow-wave sleep, and number of sleep stage changes were unaffected. Movement time was similar in both groups, but epochs with short arousal-related movements were increased in TS. Further analyses showed no significant correlations between sleep parameters and nighttime nontic movements, level of psychopathology or tic severity during daytime. Periodic limb movements during sleep (PLMS) were only seen in one TS patient (low PLMS index of 7.8/h). Conclusions: Children with TS have disturbed sleep quality with increased arousal phenomena, which both may be intrinsic to the disorder and might trigger tics and other behavioral problems during daytime. This indicates the need for sleep evaluation in patients with TS. (C) 2003 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/S0022-3999(02)00602-5"],["dc.identifier.isi","000184078300005"],["dc.identifier.pmid","12842228"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45714"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","International Conference of the Tourette-Syndrome-Foundation-of-Canada"],["dc.relation.eventlocation","MISSISSAUGA, CANADA"],["dc.relation.issn","0022-3999"],["dc.title","Disturbed sleep in children with Tourette syndrome - A polysomnographic study"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","11"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Roher, C."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:16:09Z"],["dc.date.available","2018-11-07T10:16:09Z"],["dc.date.issued","2006"],["dc.description.abstract","Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Objective: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p <= 0.005; p <= 0.035; p <= 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p <= 0.002; p <= 0.05, respectively) and cortisol (p <= 0.005; p <= 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p <= 0.0001) and olanzapine (p <= 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning."],["dc.identifier.doi","10.1007/s00213-005-0279-x"],["dc.identifier.isi","000235547600002"],["dc.identifier.pmid","16432682"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40980"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0033-3158"],["dc.title","The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","453"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Voderholzer, U."],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Berger, M."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T09:00:49Z"],["dc.date.available","2018-11-07T09:00:49Z"],["dc.date.issued","2001"],["dc.description.abstract","Background: Over recent years, the use of antidepressants for the symptomatic treatment of insomnia has grown substantially, but controlled studies are still lacking. Our study is the first investigation to prove objective efficacy and tolerability of low doses of a sedating antidepressant in a randomized, double-blind, and placebo-controlled manner in patients with primary insomnia. Method: Forty seven drug-free patients meeting DSM-IV criteria for primary insomnia (mean +/- SD duration of complaints = 11.2 +/- 9.7 years) received either 25-50 mg of the tricyclic antidepressant doxepin or placebo for 4 weeks followed by 2 weeks of placebo withdrawal. Sleep was measured by polysomnography at baseline and the first night of application, at 4 weeks of treatment and the first to third night of withdrawal, and after 2 weeks of withdrawal. Results: In the doxepin-treated patients who completed the study (N = 20, 47.6 +/- 11.3), medication significantly increased sleep efficiency after acute (night 1, p less than or equal to .001) and subchronic (night 28, p less than or equal to .05) intake compared with the patients who received placebo (N = 20, 47.4 +/- 16.8 years of age). Latency to sleep onset was not affected since the patients had normal baseline sleep latencies. Investigators found doxepin to cause significantly (P less than or equal to .05) better global improvement at the first day of treatment. Patients rated sleep quality (p less than or equal to .001) and working ability (p less than or equal to .005) to be significantly improved by doxepin during the whole treatment period. Overall rebound in sleep parameters was not observed, but patients with severe rebound insomnia were significantly more frequent in the doxepin group (night 29, p less than or equal to .01; night 30, p less than or equal to .01; night 31, p less than or equal to .05). No significant group differences in side effects were Found, but 2 doxepin-treated patients dropped out of the study due to specific side effects (increased liver enzymes, leukopenia, and thrombopenia). Conclusion: The results support the effectiveness of low doses of doxepin to improve sleep and working ability in chronic primary insomniacs, although subjective effects were light to moderate, and in some patients, rebound insomnia and specific side effects have to be considered."],["dc.identifier.isi","000169918900009"],["dc.identifier.pmid","11465523"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24262"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Berger, C."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Niedmann, P."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:36:46Z"],["dc.date.available","2018-11-07T10:36:46Z"],["dc.date.issued","2003"],["dc.identifier.isi","000186262800150"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45404"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.title","Serum homocysteine in obstructive sleep apnea syndrome can be lowered by CPAP-therapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","161"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Neuroscience Letters"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","360"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Guan, Z."],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:49:33Z"],["dc.date.available","2018-11-07T10:49:33Z"],["dc.date.issued","2004"],["dc.description.abstract","The pathophysiology of periodic leg movements (PLMs) in sleep remains to be elucidated. Among other hypotheses all alteration of dopaminergic function has been suggested. Nocturnal urinary dopamine and 4-hydroxy-3-methoxyphenylacetic acid excretion in otherwise healthy subjects with PLMs was significantly reduced (P < 0.001 and P < 0.05, respectively) compared to subjects without PLMs. This finding, for the first time, demonstrates a correlate of a functionally relevant hypoactivity of the dopaminergic system in subjects with PLMs. (C) 2004 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.neulet.2004.02.056"],["dc.identifier.isi","000221141400013"],["dc.identifier.pmid","15082158"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48459"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ireland Ltd"],["dc.relation.issn","0304-3940"],["dc.title","Nocturnal urinary dopamine excretion is reduced in otherwise healthy subjects with periodic leg movements in sleep"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Guan, Z."],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:36:45Z"],["dc.date.available","2018-11-07T10:36:45Z"],["dc.date.issued","2003"],["dc.format.extent","217"],["dc.identifier.isi","000186262800047"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45399"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Quetiapine improves sleep quality in healthy subjects"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]